Mesenchymal Stem Cells Improve Glycometabolism and Liver Regeneration in the Treatment of Post-hepatectomy Liver Failure

Conclusion: Mesenchymal stem cell transplantation could be use as a potential treatment for PHLF. Introduction Partial hepatectomy is an important treatment for benign and malignant liver diseases. Although the liver can be completely regenerated after partial excision or injury, at least 1/3 of the liver should be retained in most of the patients, and 40–50% should be retained in patients with parenchymal liver disease (Adams et al., 2013; Cieslak et al., 2014). Postoperative complications, such as acute post-hepatectomy liver failure (PHLF) or small liver syndrome, may occur when the scope of excision is too large or the remaining liver is inadequate to maintain normal liver function. As a serious challenge to patient survival, PHLF is the main cause of death after liver surgery (Schreckenbach et al., 2012; Asenbaum et al., 2018). Although surgery and postoperative care have been greatly improved, the incidence of PHLF is between 0.7 and 9% (van den Broek et al., 2008). Therefore, the treatment for PHLF is problematic and needs to be improved. At present, the most effective therapy for PHLF is liver transplantation. Although liver transplantation has a beneficial therapeutic effect, the insufficient donor liver and the high cost of this operation limit the number of liver transplantations performed (Donnelly et al., 2016). Although symptomatic support therapy can help to prevent the progression of PHLF, it is unsatisfactory for preventing sequelae and improv...
Source: Frontiers in Physiology - Category: Physiology Source Type: research